Last reviewed · How we verify

Botox-Tend — Competitive Intelligence Brief

Botox-Tend (Botox-Tend) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Botulinum toxin derivative. Area: Orthopedics / Musculoskeletal.

phase 3 Botulinum toxin derivative Acetylcholine release at neuromuscular junction (SNARE complex) Orthopedics / Musculoskeletal Small molecule Live · refreshed every 30 min

Target snapshot

Botox-Tend (Botox-Tend) — National Cheng-Kung University Hospital. Botox-Tend is a botulinum toxin-based therapeutic designed to reduce muscle tension and improve tendon function through localized neuromuscular blockade.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Botox-Tend TARGET Botox-Tend National Cheng-Kung University Hospital phase 3 Botulinum toxin derivative Acetylcholine release at neuromuscular junction (SNARE complex)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Botulinum toxin derivative class)

  1. National Cheng-Kung University Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Botox-Tend — Competitive Intelligence Brief. https://druglandscape.com/ci/botox-tend. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: